• 1
    Sutherland C. What are the bona fide GSK3 substrates [serial online]? Int J Alzheimers Dis 2011;2011:505607.
  • 2
    Ferrer I, Gomez-Isla T, Puig B, Freixes M, Ribe E, Dalfo E, Avila J. Current advances on different kinases involved in tau phosphorylation, and implications in Alzheimer's disease and tauopathies. Curr Alzheimer Res 2005;2:3-18.
  • 3
    Wang JZ, Grundke-Iqbal I, Iqbal K. Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration. Eur J Neurosci 2007;25:59-68.
  • 4
    Stamelou M, de Silva R, Arias-Carrion O, et al. Rational therapeutic approaches to progressive supranuclear palsy. Brain 2010;133:1578-1590.
  • 5
    Ferrer I, Barrachina M, Puig B. Glycogen synthase kinase-3 is associated with neuronal and glial hyperphosphorylated tau deposits in Alzheimer's disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Acta Neuropathol 2002;104:583-591.
  • 6
    Medina M, Castro A. Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic. Curr Opin Drug Discov Devel 2008;11:533-543.
  • 7
    Martinez A, Alonso M, Castro A, Perez C, Moreno FJ. First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J Med Chem 2002;45:1292-1299.
  • 8
    Dominguez JM, Fuertes A, Orozco L, del Monte-Millan M, Delgado E, Medina M. Evidence for the irreversible inhibition of glycogen synthase kinase-3beta by tideglusib. J Biol Chem 2000;287:893-904.
  • 9
    Sereno L, Coma M, Rodriguez M, et al. A novel GSK-3β inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo. Neurobiol Dis 2009;35:359-367.
  • 10
    Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP International Workshop. Neurology 1996;47:1-9.
  • 11
    Golbe LI. The Medical Advisory Board of the Society for Progressive Supranuclear Palsy. A clinical rating scale and staging system for progressive supranuclear palsy. Neurology 1997;48(suppl):A326.
  • 12
    Wahlund LO, Barkhof F, Fazekas F, et al. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 2001;32:1318-1322.
  • 13
    Golbe LI, Ohman-Strickland PA. A clinical rating scale for progressive supranuclear palsy. Brain 2007;130:1552-1565.
  • 14
    Jurica PJ, Leitten CL, Mattis S. Dementia Rating Scale-2 Professional Manual. Lutz, FL: Psychological Assessment Resources; 2001.
  • 15
    Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a Frontal Assessment Battery at bedside. Neurology 2000;55:1621-1626.
  • 16
    Guy W. Clinical Global Impressions: In: Guy W, editor. ECDEU Assessment Manual for Psychopharmacology. Revised DHEW Publication (ADM). Rockville, MD: National Institute for Mental Health; 1976; 218-222.
  • 17
    Schwab RS, England AC. Projection technique for evaluating surgery in Parkinson's disease. In: Gillingahm FJ, Donaldson IML, editors. Third Symposium on Parkinson's Disease. Edinburgh, UK: Livingston; 1969:152-157.
  • 18
    Huppertz HJ, Kroll-Seger J, Kloppel S, Ganz RE, Kassubek J. Intra- and interscanner variability of automated voxel-based volumetry based on a 3D probabilistic atlas of human cerebral structures. Neuroimage 2010;49:2216-2224.
  • 19
    Frings L, Mader I, Landwehrmeyer BG, Weiller C, Hull M, Huppertz HJ. Quantifying change in individual subjects affected by frontotemporal lobar degeneration using automated longitudinal MRI volumetry. Hum Brain Mapp 2011;33:1526-1535.
  • 20
    Freeborough PA, Fox NC. The boundary shift integral: an accurate and robust measure of cerebral volume changes from registered repeat MRI. Trans Med Imaging 1997;16:623-629.
  • 21
    Benjamini Y, Yekutieli D. The control of the false discovery rate in multiple testing under dependency. Ann Stat 2000;29:1165-1188.
  • 22
    Raman R, Thomas RG, Weiner MW, et al. MRI substudy participation in Alzheimer disease (AD) clinical trials: baseline comparability of a substudy sample to entire study population. Alzheimer Dis Assoc Disord 2009;23:333-336.
  • 23
    Oba H, Yagishita A, Terada H, et al. New and reliable MRI diagnosis for progressive supranuclear palsy. Neurology 2005;64:2050-2055.
  • 24
    Quattrone A, Nicoletti G, Messina D, et al. MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy. Radiology 2008;246:214-221.
  • 25
    Morelli M, Arabia G, Novellino F, et al. MRI measurements predict PSP in unclassifiable parkinsonisms: a cohort study. Neurology 2011;77:1042-1047.
  • 26
    Whitwell JL, Xu J, Mandrekar JN, Gunter JL, Jack CR Jr, Josephs KA. Rates of brain atrophy and clinical decline over 6 and 12-month intervals in PSP: determining sample size for treatment trials. Parkinsonism Relat Disord 2012;18:252-256.
  • 27
    Williams DR, Holton JL, Strand C, Pittman A, de Silva R, Lees AJ, Revesz T. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome. Brain 2007;130:1566-1576.